Tirzepatide for weight loss is one of the most effective medications available in 2026 — clinical trials show average body weight reductions of 20–22% over 72 weeks, outperforming every other approved GLP-1 agent. This guide covers the full dosing schedule, what results to expect at each phase, and the side effects you need to manage.

TL;DR

Tirzepatide (brand name Zepbound for obesity, Mounjaro for type 2 diabetes) is a dual GIP/GLP-1 receptor agonist injected once weekly. Starting dose is 2.5 mg; the maintenance ceiling is 15 mg. In the SURMOUNT-1 trial (2022, n=2,539), participants on 15 mg lost an average of 22.5% of body weight over 72 weeks. Common side effects — nausea, diarrhea, constipation — are dose-dependent and peak during titration. A licensed provider through Good Life Health's medical weight loss program can prescribe and supervise the full protocol.

Key Takeaways
  • Tirzepatide is a dual GIP/GLP-1 receptor agonist injected once weekly.
  • The dose starts at 2.5 mg and titrates to a 15 mg maintenance ceiling.
  • In SURMOUNT-1, participants on 15 mg lost an average 22.5% of body weight over 72 weeks.
  • Side effects (nausea, diarrhea, constipation) are dose-dependent and peak during titration.
  • Not every patient needs to reach 15 mg; some hold a lower dose if losing consistently.
  • Weight regain after stopping is well-documented, so it is generally a long-term medication.

Why This Matters in 2026

Tirzepatide is not semaglutide with a new label. It hits two separate receptors — GIP and GLP-1 — which produces greater appetite suppression and a metabolic effect semaglutide cannot replicate at any dose. The FDA approved tirzepatide for chronic weight management (as Zepbound) in November 2023. By 2026, it remains the highest-efficacy approved injectable for obesity outside of bariatric surgery. If you are evaluating weight-loss options, this is the benchmark everything else gets measured against.

What You'll Need

  • A prescription from a licensed medical provider (tirzepatide is not available OTC)
  • Auto-injector pens: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg single-dose
  • A consistent injection site: abdomen, thigh, or upper arm (rotate each week)
  • A sharps disposal container
  • A low-fat, high-protein dietary baseline — high-fat meals significantly worsen GI side effects during titration
  • Roughly 15–30 minutes per week for injection and symptom tracking
  • Access to a provider for monthly or quarterly check-ins

---

The Dosing Protocol — Step by Step

Step 1: Start at 2.5 mg for Weeks 1–4

The 2.5 mg starting dose is a tolerability dose, not a therapeutic dose. Its only job is to let your GI tract adapt. Inject subcutaneously once weekly on the same day each week. Most people experience minimal weight loss at this stage — that is expected.

Clinical note

The 2.5 mg starting dose is a tolerability dose, not a therapeutic one — its only job is to let the GI tract adapt. Advancing too fast dramatically increases nausea and dropout; do not advance to 7.5 mg until you have tolerated 5 mg for a full 4 weeks.

The common mistake here is skipping the 4-week on-ramp because "it isn't working yet" and jumping to 5 mg too fast, which dramatically increases nausea and dropout.

Expected outcome: Little to no weight change. GI discomfort is mild or absent for most people.

Step 2: Titrate to 5 mg for Weeks 5–8

At week 5, increase to 5 mg. This is where appetite suppression becomes noticeable. Most people reduce calorie intake by 300–600 kcal/day without consciously trying. Nausea risk increases here — take the injection before bed and eat smaller, lower-fat meals on injection day. Do not advance to 7.5 mg until you have tolerated 5 mg for a full 4 weeks.

Expected outcome: 2–4% body weight loss by week 8 in clinical data.

Step 3: Advance to 7.5 mg for Weeks 9–12

The jump from 5 mg to 7.5 mg is where most people first see substantial weight loss velocity. Hunger cues flatten significantly at this dose. Constipation, rather than nausea, becomes the primary complaint for many patients. Increase fiber and water intake proactively — waiting until constipation is severe makes it harder to manage. If side effects at 7.5 mg are not tolerable after 4 weeks, remain at 5 mg rather than forcing the escalation.

Expected outcome: Cumulative 5–8% body weight loss by week 12, based on SURMOUNT-1 data.

Step 4: Escalate to 10 mg for Weeks 13–16

By week 13, your GI system has adapted enough that 10 mg is tolerable for most people. This is roughly the midpoint of the therapeutic range. Weight loss continues at a meaningful rate. Your provider may order a metabolic panel here to check blood glucose, lipids, and kidney function — standard practice for anyone on a GLP-1 or GIP/GLP-1 agent beyond 12 weeks.

Expected outcome: Cumulative 10–13% body weight loss by week 16.

Step 5: Move to 12.5 mg for Weeks 17–20

Not everyone needs to advance past 10 mg. If you are losing 0.5–1% of body weight per week consistently at 10 mg, some providers hold that dose rather than escalating. The 12.5 mg dose is appropriate when weight loss plateaus. Side effects at this level are similar in character to 10 mg but slightly higher in frequency. The most common new complaint at 12.5 mg is reflux — do not eat within 2–3 hours of lying down.

Expected outcome: Cumulative 14–17% body weight loss by week 20.

Step 6: Reach Maintenance at 15 mg (Week 21+)

15 mg is the FDA-approved maximum dose. Not every patient reaches it, and not every patient needs it — roughly 50% of SURMOUNT-1 participants on the 10 mg arm achieved clinically meaningful weight loss (≥5%) without escalating further. At 15 mg, the full dual-receptor effect is active. Weight loss typically continues through week 52–72 before plateauing. This is a long-term maintenance dose, not a short sprint.

Expected outcome: 20–22% average body weight reduction at 72 weeks on 15 mg (SURMOUNT-1, 2022).

Tirzepatide weight loss by phase (SURMOUNT-1)
22.5%
mean body weight lost on 15 mg over 72 weeks
10–13%
cumulative loss by week 16 (10 mg)
5–8%
cumulative loss by week 12 (7.5 mg)

---

Troubleshooting

Nausea that disrupts daily function: Drop back one dose level for 4 weeks before re-escalating. Persistent severe nausea is not something to push through — it causes dehydration and drives dropout.

Weight loss stalls after week 20: Rule out adherence issues (missed injections), then evaluate whether you are at your maximum tolerated dose. Plateau at a sub-maximum dose is a signal to escalate, not to stop.

Severe constipation: Increase fiber to 25–35 g/day, drink at least 2.5 liters of water daily, and add a stool softener if needed. Do not wait until you are impacted.

Injection site reactions (redness, itching, nodule): Rotate the injection site every week across at least 3 anatomical zones. Lumps from repeated injection into the same spot resolve over several weeks once rotation is established.

Hair thinning (telogen effluvium): Reported in roughly 5.7% of patients in SURMOUNT-1. It is a response to rapid calorie deficit and rapid weight loss, not a direct drug effect. Maintain protein intake above 1.2 g/kg of body weight per day. Most cases resolve within 3–6 months.

Muscle loss: Tirzepatide preserves lean mass better than calorie restriction alone, but loss still occurs at high velocity weight loss. Resistance training at least 2x per week is the evidence-based mitigation.

---

Tools and Resources

  • Prescribing provider: Tirzepatide requires a prescription. Good Life Health offers medical weight loss services that include GLP-1 and dual-agonist protocols supervised by licensed clinicians.
  • Membership plan: For ongoing prescription management and check-ins, review the Good Life Health membership options.
  • Patient reviews: See reported outcomes from current patients on the reviews page.
  • Injection supplies: Auto-injector pens are dispensed by pharmacy with the prescription. A sharps container is typically under $10 at any pharmacy.
  • Dietary tracking app: Any calorie-logging app works — the goal is confirming protein targets, not counting every macro obsessively.

---

What to Do Next

If you are ready to start, the first move is getting a clinical evaluation to confirm you qualify (BMI ≥30, or ≥27 with a weight-related comorbidity per FDA criteria). For a deeper comparison of tirzepatide against semaglutide — including which patients do better on each — see the tirzepatide vs semaglutide comparison guide.

---

FAQ

What is the starting dose of tirzepatide for weight loss? The standard starting dose is 2.5 mg once weekly. This dose is for GI tolerance only — meaningful weight loss begins during the 5 mg and 7.5 mg phases.

How much weight can you lose on tirzepatide? In the SURMOUNT-1 trial (2022, n=2,539), participants on 15 mg lost an average of 22.5% of body weight over 72 weeks. Individual results depend on starting weight, adherence, diet, and activity level.

How long does it take to see results with tirzepatide? Most people notice appetite suppression by weeks 5–8 (5 mg dose). Visible weight loss — 5% or more — typically appears by weeks 10–14 for adherent patients.

What are the most common side effects of tirzepatide? Nausea, diarrhea, constipation, and vomiting. These are dose-dependent and most intense during dose escalation. They decrease significantly once you stabilize at a maintenance dose.

Is tirzepatide better than semaglutide for weight loss? Head-to-head data from the SURMOUNT-5 trial (2025) showed tirzepatide produced 47% more weight loss than semaglutide 2.4 mg over 72 weeks. Tirzepatide wins on average efficacy; semaglutide may suit patients who tolerate GIP receptor activity less well.

Can you stop tirzepatide once you reach your goal weight? Weight regain after stopping is well-documented. The SURMOUNT-4 trial (2023) showed participants who stopped tirzepatide regained two-thirds of lost weight within 52 weeks. Most clinical guidelines treat it as a long-term or indefinite medication, similar to antihypertensives.

Does tirzepatide require a prescription in 2026? Yes. Tirzepatide (Zepbound, Mounjaro) is a Schedule — wait, it is not scheduled — but it is an FDA prescription-only medication. No legal source dispenses it without a valid prescription from a licensed provider.

What does tirzepatide cost per month? List price for Zepbound is approximately $1,060–$1,350/month without insurance in 2026. Eli Lilly's savings card reduces out-of-pocket to as low as $550/month for eligible commercially insured patients. Compounded tirzepatide from licensed compounding pharmacies has been available at lower cost, though FDA oversight of compounders tightened in late 2024.

---

One Last Thing

Tirzepatide suppresses hunger partly by slowing gastric emptying — the same mechanism that makes oral medications less predictable when taken alongside it. If you take thyroid medication, oral contraceptives, or any drug where consistent absorption matters, tell your prescribing provider before starting. The interaction is manageable but requires timing adjustments that most patients are never told about upfront.

---

Related Guides

References

  1. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). 2022. pubmed.ncbi.nlm.nih.gov/35658024/
  2. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). 2021. pubmed.ncbi.nlm.nih.gov/33567185/